Five Prime Therapeutics nets $66.7mm via IPO
Executive Summary
Protein and antibody drug developer Five Prime Therapeutics Inc. netted $66.7mm in its initial public offering of 5.52mm common shares (including the overallotment) at $13 each. The company had planned to sell 4mm shares between $12 and $14.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Genomics-Proteomics
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- IPO
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice